"This is our Watson and Crick moment" Midatech CEO"No other company or acedemic institution has been able to do what we've done. We could have the world's first long acting injectable protein. Let me just say that it is not often that small companies like ours make these kinds of scientific leaps. This really is our Watson and Crick moment." Stephen Stamp CEO Midatech June 17, 2021
"The Company believes these results could potentially open up very significant opportunities for its Q-Sphera technology. A significant number of latest generation medicines are protein based and reformulation as long-acting injectables could provide significant benefits to patients, physicians and payors. In 2020, the top 10 mAbs recorded aggregate sales of US$74.9 billion1 and all mAbs US$154 billion1 globally." June 17, 2021
"Following expansion of the R&D collaboration agreement with Janssen for encapsulation of its experimental monoclonal antibody, the company is working on developing methods for encapsulation of bispecific T cell engager molecules and antibody-drug conjugates, both of which have shown utility in oncology and present considerable market opportunity." Edison Group November 15, 2022
"We continue to believe there is substantial value to be unlocked from Midatech's MTX110, particularly in our ongoing phase I clinical trial in GBM, and to leverage our Q-Sphera technology. In combination with Bioasis' promising development pipeline we have the opportunity to create a much stronger group and transition from a drug delivery platform-based company to a therapeutics company." Stephen Stamp CEO Midatech December 13, 2022